Methylxanthine Treatment in Neonates Admitted to the Special Care Unit: An Observational Study in Low-Resource Settings
by
, , , , and
Martina Borellini
1,
Francesco Cavallin
2,
Nasri Mfaume
3,
Eleni Hagos Giday
4,
Tarikua Endrias
5,
Jiksa Tolera
5,
Paolo Belardi
1,
Fabio Manenti
6,
Giovanni Putoto
6,
Luigi Pisani
7,8 and
Daniele Trevisanuto
9,*
1
Doctors with Africa CUAMM, Iringa P.O. Box 11, Tanzania
2
Independent Statistician, 36020 Solagna, Italy
3
Tosamaganga Regional Referral Hospital, Iringa P.O. Box 11, Tanzania
4
Doctors with Africa CUAMM, Wolisso P.O. Box 250, Ethiopia
5
St. Luke Catholic Hospital and College of Nursing and Midwifery, Wollisso P.O. Box 250, Ethiopia
6
Doctors with Africa CUAMM, 35121 Padua, Italy
7
Department of Precision-Regenerative Medicine and Jonic Area (DiMePRe-J), Section of Anesthesiology and Intensive Care Medicine, University of Bari “Aldo Moro”, 70121 Bari, Italy
8
Mahidol Oxford Tropical Research Unit (MORU), Bangkok 10400, Thailand
9
Department of Woman’s and Child’s Health, University of Padua, 35128 Padova, Italy
*
Author to whom correspondence should be addressed.
Children 2026, 13(1), 54; https://doi.org/10.3390/children13010054 (registering DOI)
Submission received: 6 December 2025
/
Revised: 24 December 2025
/
Accepted: 29 December 2025
/
Published: 30 December 2025
(This article belongs to the Section Global Pediatric Health)
Highlights
What are the main findings?
- In two Sub-Saharan settings, methylxanthine treatment for apnea of prematurity was limited to aminophylline, which was given to around 12% of infants admitted to the special care units.
- Overall, the treatment was appropriately given to most eligible neonates, although a considerable subgroup of very preterm infants did not receive aminophylline prophylaxis.
What is the implication of the main finding?
- Further studies may investigate the reasons for protocol incompliance regarding aminophylline treatment and healthcare staff’s opinions on such an aspect.
- Use of caffeine in these settings may improve adherence to therapeutic protocols.
Abstract
Background: The appropriate identification of target patients for methylxanthine therapy may optimize resource allocation and improve clinical outcomes, but data on routine care in low-resource settings are limited. Our study assessed methylxanthine use in clinical practice in two Sub-Saharan settings. Methods: This retrospective, registry-based study investigated methylxanthine use in newborns who were admitted to Tosamaganga Hospital (Tanzania) and Wolisso Hospital (Ethiopia) in 2022–2023. The prevalence and type of methylxanthine treatment were investigated. Neonates receiving methylxanthine were compared to those not receiving it in terms of baseline characteristics, clinical data, treatments, and discharge information. All data were retrieved from local registries. Results: Aminophylline was administered to 196/1674 neonates (11.7%), while caffeine was not available in these settings. This treatment was more common in preterm and smaller infants (p < 0.0001), asphyxiated neonates (p < 0.0001), and the sickest patients (p < 0.001). The need for respiratory support (p < 0.0001), intravenous lines (p < 0.0001), and antibiotic therapy (p < 0.0001), as well as the length of hospital stay (p < 0.0001) and mortality rate (p < 0.0001), were higher in neonates receiving aminophylline. Conclusions: In two Sub-Saharan settings, methylxanthine treatment was limited to aminophylline, which was given to around 12% of infants admitted to the special care units. Overall, the treatment was appropriately given to most eligible neonates, although a considerable subgroup of very preterm infants did not receive aminophylline prophylaxis. Further studies may investigate the reasons for protocol incompliance regarding aminophylline treatment and healthcare staff’s opinions on such an aspect.
1. Introduction
Prematurity is the main cause of under-five mortality and long-term morbidity [1]. In 2020, over 13 million newborn babies were estimated to be born before 37 weeks gestation worldwide, without relevant changes over the last decade [2].
The healthcare burden on morbidity is expected to rise because of the increasing survival of very preterm infants. Hence, the prevention of prematurity-related complications remains a global health urgency [3,4].
Respiratory distress and apnea of prematurity are common complications in preterm infants [5]. These have been mainly treated with invasive ventilatory support [5,6], but non-invasive respiratory strategies have been implemented in recent decades to reduce the consequences of mechanical ventilation [6,7]. Nonetheless, these strategies may be insufficient in patients with severe respiratory distress or frequent episodes of apnea [7].
In such patients, methylxanthines such as caffeine and aminophylline are routinely given to prevent conversion from non-invasive to invasive ventilatory support [5]. The drug effects include improved stimulation of respiratory drive and enhanced diaphragmatic contractility, with clinical advantages in reducing mechanical ventilation, apnea and bronchopulmonary dysplasia, and long-term neurodevelopmental impairment [8]. Caffeine is the most used methylxanthine thanks to its ease of use, long half-life, and extensive therapeutic range and is included in the list of essential drugs by the World Health Organization [9,10]. Although caffeine is recommended as first-line therapy (followed by aminophylline when caffeine is unavailable), aminophylline is still widely used in low-resource settings due to cost and shortage of caffeine [11,12].
Appropriate identification of target patients for methylxanthine treatment may optimize resource allocation and improve the outcome of preterm infants. However, data on methylxanthine use in clinical practice in low-resource settings are limited. Our study assessed this aspect in two Sub-Saharan settings, aiming to provide useful information to clinicians.
2. Materials and Methods
2.1. Study Design
This retrospective, observational, registry-based study investigated methylxanthine use in newborns who were admitted to Tosamaganga Hospital (Tanzania) and Wolisso Hospital (Ethiopia) in 2022–2023. The study was approved by the local Review Boards (protocol number NIMR/HQ/R.8a/Vol.IX/5055 and Ref. No BFO/HQ/093/17). The local registries are parts of the Critical Care Asia Africa (CCAA) federated network of registries. The registries received ethical approval, and a waiver of informed consent was provided from the local review boards [13,14]. The investigations were conducted in accordance with the principles of the Declaration of Helsinki.
2.2. Setting
Tosamaganga Regional Referral Hospital (Tosamaganga Hospital) is a non-profit, secondary-level hospital in the Iringa District Council; this is a rural district in Southwestern Tanzania covering around 320,000 people. St. Luke Catholic Hospital in Wolisso (Wolisso Hospital) is a non-profit, tertiary-level hospital in Wolisso town; this is the capital of the Southwest Shoa Zone in the Oromiya region (Ethiopia) with about 1.1 million inhabitants. Both hospitals account for about 3500–3600 deliveries per year. Aminophylline is the only available methylxanthine for the prevention and treatment of apnea of prematurity. At Tosamaganga Hospital, all newborns with birth weight < 1600 g or gestational age < 34 weeks receive prophylactic treatment with aminophylline; the treatment is stopped before discharge in patients reaching 1500 g or 34 weeks gestation. At Wolisso Hospital, all newborns with birth weight < 1500 g or gestational age < 34 weeks receive prophylactic treatment with aminophylline; the treatment is stopped before discharge in patients without apnea episodes in the last 7 days or reaching 34 weeks of gestation. In both hospitals, all newborns with apnea episodes may receive aminophylline according to the decision of the attending physician.
2.3. Patients
All neonates admitted to the Special Care Units of the participating hospitals between 1 January 2022 and 31 December 2023 were retrospectively included in the study. The only exclusion criterion was the unavailability of information on methylxanthine use.
2.4. Data Collection
All data were retrieved from the local registries and collected in a dedicated electronic spreadsheet after being anonymized. Data collection included the participating hospital, baseline characteristics (source of admission, maternal history, delivery, neonatal demographics), clinical information (Apgar score at 5 min, temperature, oxygen saturation), respiratory support, aminophylline treatment, neonatal diagnoses, and discharge information (hospital length of stay, respiratory support during hospital stay, intravenous line, antibiotic therapy, kangaroo mother care, feeding, and discharge status).
2.5. Statistical Analysis
Numerical data were summarized as median and interquartile range (IQR), while categorical data were summarized as absolute and relative frequency (percentage). Data were compared between the two groups using the Mann–Whitney test (continuous data) and Fisher’s test or the chi-squared test (categorical data). Effect sizes were reported as median difference or odds ratio (ORs) with 95% confidence intervals (CIs). All tests were two-sided, and a p-value <0.05 was considered statistically significant. Statistical analysis was carried out using R 4.4 (R Foundation for Statistical Computing, Vienna, Austria) [15].
3. Results
During the study period, aminophylline was administered to 196 out of 1674 neonates (prevalence of 11.7%; 95% confidence interval 10.2–13.4%) who were admitted to the special care units of the participating hospitals. Information on methylxanthine use was unavailable in 280 other neonates.
The baseline characteristics are summarized in Table 1. Receiving aminophylline was more frequent in outborn neonates (OR 2.29, 95% CI 1.51 to 3.48; p < 0.0001), multiple births (OR 4.41, 95% CI 3.03 to 6.41; p < 0.0001), and neonates born through assisted breech (OR 3.97, 95% CI 1.95 to 9.07; p < 0.0001). Mothers with preeclampsia/eclampsia were more likely to give birth to a neonate requiring aminophylline (OR 3.65, 95% CI 1.85 to 8.09; p < 0.0001). Meconium-stained amniotic fluid was associated with a lower likelihood of receiving aminophylline (OR 0.55, 95% CI 0.33 to 0.90; p = 0.002). Overall, aminophylline was administered more frequently in preterm infants (OR 17.48, 95% CI 11.77 to 25.97; p < 0.0001), low-birth-weight infants (OR 20.16, 95% CI 12.95 to 31.40; p < 0.0001), and those with an Apgar score < 7 at 5 min (OR 2.37, 95% CI 1.66 to 3.41; p < 0.0001), lower temperature (median difference −1.0, 95% CI −1.2 to −0.8; p < 0.0001), or lower transcutaneous oxygen saturation (median difference −1.0, 95% CI −1.9 to −0.1; p = 0.005). Aminophylline was also administered more frequently in infants requiring more respiratory support (OR 15.53, 95% CI 10.28 to 23.48; p < 0.0001).
Neonatal diagnoses are reported in Table 2. Receiving aminophylline was more frequent in neonates with respiratory distress syndrome (OR 7.39, 95% CI 5.16 to 10.60; p < 0.0001), asphyxia (OR 1.64, 95% CI 1.16 to 2.33; p = 0.007), or prematurity (OR 16.09, 95% CI 11.33 to 22.86; p < 0.0001). On the other hand, receiving aminophylline was less frequent in neonates with pneumonia/sepsis/meconium aspiration syndrome (OR 0.50, 95% CI 0.36 to 0.71; p = 0.0001), congenital malformations (OR 0.15, 95% CI 0.01 to 0.86; p = 0.04), feeding problems (OR 0.00, 95% CI 0.00 to 0.71; p = 0.01), or hyperbilirubinemia (OR 0.22, 95% CI 0.11 to 0.40; p < 0.0001).
Discharge information is displayed in Table 3. Hospital length of stay was longer in neonates who received aminophylline (median difference 3 days, 95% CI 2 to 4 days; p < 0.0001). During hospital stay, more respiratory support (OR 11.41, 95% CI 8.13 to 16.00; p < 0.0001), intravenous line use (OR 21.57; 8.81 to 52.79; p < 0.0001), and antibiotic therapy (OR 10.49, 95% CI 6.12 to 19.33; p < 0.0001) were more frequently administered to neonates treated with aminophylline. Moreover, they also received prolonged continuous positive airway pressure (median difference 1 day, 95% CI 1 to 2 days; p < 0.0001). Notably, kangaroo mother care was more common in neonates who received aminophylline (OR 7.65, 95% CI 5.35 to 10.95; p < 0.0001), although they were less likely to receive exclusive breastfeeding (OR 0.44, 95% C0.31 to 0.62; p < 0.0001). In the end, the mortality rate was higher in neonates who received aminophylline (OR 13.90, 95% CI 9.18 to 21.17; p < 0.0001).
4. Discussion
Our study explored the use of methylxanthines in a large cohort of infants who were admitted to neonatal special care units in Sub-Saharan settings. Our findings offered an estimate of its prevalence in clinical practice and depicted the profile of the recipients in settings where information on this topic remains limited.
In our hospitals, methylxanthine treatment was performed using aminophylline due to the unavailability of caffeine, which is common in low-resource settings due to cost and shortage of the latter [11,12,16,17]. The World Health Organization recommends caffeine for the prevention and treatment of apnea in preterm infants, while other methylxanthines (such as aminophylline or theophylline) may be considered when caffeine is unavailable [10]. Among the advantages of caffeine, the ready-to-use oral formulation without mixing and the once-per-day intake reduce the workload for healthcare staff, whereas aminophylline is given multiple times a day and needs to be diluted before use [10].
Our data showed that around 12% of infants were treated with aminophylline in the special care units. Unfortunately, we could not compare such a figure with the actual prevalence of neonates eligible for methylxanthine treatment or with previous literature on this topic. As expected, aminophylline treatment was progressively more frequent in smaller infants, who are more likely to develop apnea of prematurity [5,18]. Nonetheless, we believe that very-low-birth-weight infants might have been undertreated, because one out of three infants did not receive aminophylline prophylaxis [11]. The actual reason for this is unknown, but it may be associated with drug shortages and/or local protocols.
Overall, neonates with prematurity-associated conditions (such as preeclampsia/eclampsia, twins, lower Apgar score, lower temperature and oxygen saturation, and need for respiratory support) had a reasonably higher chance of receiving aminophylline [5]. In addition, aminophylline was also more common in asphyxiated neonates and those born through assisted breech, who are likely to develop postnatal respiratory impairment. Despite the advantage of methylxanthines in such cases, the reasons for this impairment are still unclear [19,20]. On the other hand, aminophylline was less frequently given to neonates with a primary diagnosis not associated with apnea episodes (such as meconium-stained amniotic fluid, congenital malformations, feeding problems, or hyperbilirubinemia), according to international recommendations [10].
As predicted, discharge information displayed a picture of neonates treated with aminophylline who were sicker compared to the others. In fact, they required more therapeutic support (such as non-invasive respiratory support, intravenous lines, and antibiotic therapy) during a prolonged hospital stay, which is expected to be associated with the preterm condition [4]. This consideration about severity aligned with the increased mortality rate among this group of patients. Improving the survival of small vulnerable newborns in low-resource settings requires the optimization of available assets and additional human and technological resources [21]. In addition, sicker babies may benefit from a short-term follow-up visit after discharge, as suggested by a recent study on neonatal readmission [22].
Kangaroo mother care is strongly recommended in all preterm or low-birth-weight infants to improve neonatal outcomes such as mortality, infection, weight gain, and breastfeeding [11]. In our study, kangaroo mother care was more common in neonates who received aminophylline as appropriate according to the premature condition. However, there was still room for improvement in routine care, since many preterm infants did not receive kangaroo mother care.
This study has some limitations that should be considered by the reader. First, the retrospective design limited the availability of some information such as the dose and timing of aminophylline treatment; hence, we could not exclude that some suboptimal dose/timing of the therapy might have influenced the clinical outcomes. The reasons for protocol incompliance regarding aminophylline treatment could include aspects such as drug shortage or healthcare staff’s motivations [16], but this information was not available and could not be investigated. In addition, caffeine has been associated with fewer side effects compared to aminophylline [12] but, unfortunately, data on aminophylline-related side effects were not available in the registry records. Therefore, we could not draw any conclusions about adverse events after aminophylline treatment or make any comparisons with caffeine treatment. Second, the information retrieved from the clinical charts did not allow for a full evaluation of disease severity, which could have influenced treatment efficacy and clinical outcomes. Third, the generalizability of the findings should be limited to similar settings.
Our findings suggest that the current data registry may be improved by adding specific items about disease severity, dose/timing, and adverse events of methylxanthine treatment. Further studies may evaluate protocol deviations and their reasons in order to improve the quality of the treatment. Future development may locally implement caffeine use for apnea of prematurity and assess the improvement with a before–after study.
5. Conclusions
In two Sub-Saharan settings, methylxanthine treatment involved around 12% of infants admitted to special care units and was limited to aminophylline due to the unavailability of caffeine. Overall, the treatment was appropriately given to most eligible neonates, although a considerable subgroup of very preterm infants did not receive aminophylline prophylaxis and require further attention. Local healthcare providers may investigate protocol deviations and reasons to improve the quality of the treatment. Local registries may be updated by including more information on methylxanthine treatment such as dose, timing, and adverse events. Further studies may investigate the reasons for protocol incompliance regarding aminophylline treatment and healthcare staff’s opinions on such an aspect.
Author Contributions
Conceptualization, M.B., F.C., L.P. and D.T.; methodology, N.M., E.H.G. and P.B.; formal analysis, F.C.; investigation, T.E. and J.T.; resources, F.M. and G.P.; data curation, M.B., E.H.G. and P.B.; writing—original draft preparation, M.B., F.C. and D.T.; writing—review and editing, N.M., E.H.G., T.E., J.T., P.B., F.M., G.P. and L.P.; supervision, F.M., G.P. and D.T. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
The study was approved by the local review boards, Ministry of Health, and the National Institute for Medical Research (protocol number NIMR/HQ/R.8a/Vol.IX/5055 and Ref. No. BFO/HQ/093/17), approved on 14 August 2025. The local registries are parts of the Critical Care Asia Africa (CCAA) federated network of registries and ethical approval.
Informed Consent Statement
Patient consent was waived due to the retrospective nature of this study.
Data Availability Statement
Data are available upon motivated request to the corresponding author. The data are not publicly available due to data set has not been published and the data has been retrieved from the international registry that has limited access.
Conflicts of Interest
The authors declare no conflicts of interest.
References
- United Nations Inter-Agency Group for Child Mortality Estimation (UN IGME), Report 2023. Levels and Trends in Child Mortality. Available online: https://data.unicef.org/resources/levels-and-trends-in-child-mortality-2024 (accessed on 22 August 2025).
- Ohuma, E.O.; Moller, A.B.; Bradley, E.; Chakwera, S.; Hussain-Alkhateeb, L.; Lewin, A.; Okwaraji, Y.B.; Mahanani, W.R.; Johansson, E.W.; Lavin, T.; et al. National, regional, and global estimates of preterm birth in 2020, with trends from 2010: A systematic analysis. Lancet 2023, 402, 1261–1271. [Google Scholar] [CrossRef] [PubMed]
- Decramer, M.; European Respiratory Roadmap Initiative. The European respiratory roadmap. Lancet 2011, 378, 1765–1772. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization (WHO). WHO Recommendations on Interventions to Improve Preterm Birth Outcomes; WHO: Geneva, Switzerland, 2015. [Google Scholar]
- Eichenwald, E.C.; Committee on Fetus and Newborn; American Academy of Pediatrics. Apnea of Prematurity. Pediatrics 2016, 137, e20153757. [Google Scholar] [CrossRef] [PubMed]
- Sweet, D.G.; Carnielli, V.P.; Greisen, G.; Hallman, M.; Klebermass-Schrehof, K.; Ozek, E.; Te Pas, A.; Plavka, R.; Roehr, C.C.; Saugstad, O.D.; et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update. Neonatology 2023, 120, 3–23. [Google Scholar] [CrossRef] [PubMed]
- Moschino, L.; Zivanovic, S.; Hartley, C.; Trevisanuto, D.; Baraldi, E.; Roehr, C.C. Caffeine in preterm infants: Where are we in 2020? ERJ Open Res. 2020, 6, 00330-2019. [Google Scholar] [CrossRef] [PubMed]
- Moresco, L.; Sjögren, A.; Marques, K.A.; Soll, R.; Bruschettini, M. Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants. Cochrane Database Syst Rev. 2023, 10, CD015462. [Google Scholar] [PubMed]
- Henderson-Smart, D.J.; De Paoli, A.G. Methylxanthine treatment for apnoea in preterm infants. Cochrane Database Syst. Rev. 2010, 12, CD000140. [Google Scholar] [CrossRef] [PubMed]
- WHO Model List of Essential Medicines—23rd List. 2023. Available online: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02 (accessed on 22 August 2025).
- WHO Recommendations for Care of the Preterm or Low Birth Weight Infant; World Health Organization: Geneva, Switzerland, 2022.
- Miao, Y.; Zhou, Y.; Zhao, S.; Liu, W.; Wang, A.; Zhang, Y.; Li, Y.; Jiang, H. Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis. PLoS ONE 2022, 17, e0274882. [Google Scholar] [CrossRef] [PubMed]
- Mortara, M.; Turay, M.S.; Boyle, S.; Caracciolo, C.; Bah, S.; Kargbo, H.; Hanciles, E.; John-Cole, V.; Scapini, E.; Benoni, R.; et al. Impact and burden of sickle cell disease in critically ill obstetric patients in a high dependency unit in Sierra Leone-a registry based evaluation. BMC Pregnancy Childbirth 2023, 23, 580. [Google Scholar] [CrossRef] [PubMed]
- Collaboration for Research, Implementation and Training in Critical Care—Asia Investigators; Pisani, L.; Rashan, T.; Shamal, M.; Ghose, A.; Kumar Tirupakuzhi Vijayaraghavan, B.; Tripathy, S.; Aryal, D.; Hashmi, M.; Nor, B.; et al. Performance evaluation of a multinational data platform for critical care in Asia. Wellcome Open Res. 2022, 6, 251. [Google Scholar] [CrossRef] [PubMed]
- R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2024; Available online: https://www.R-project.org/ (accessed on 22 August 2025).
- Ekhaguere, O.A.; Bolaji, O.; Nabwera, H.M.; Storey, A.; Embleton, N.; Allen, S.; Demeke, Z.; Fasawe, O.; Wariari, B.; Seth, M.; et al. A landscape evaluation of caffeine citrate availability and use in newborn care across five low- and middle-income countries. PLoS Glob. Public Health 2024, 4, e0002486. [Google Scholar] [CrossRef] [PubMed]
- Ginsburg, A.S.; Coleman, J.; Waiyego, M.; Murila, F.; Macharia, W.M.; Ochieng, R. A survey of barriers and facilitators to caffeine use for apnoea of prematurity in low- and middle-income countries. Paediatr. Int. Child Health 2022, 42, 137–141. [Google Scholar] [CrossRef] [PubMed]
- Chavez, L.; Bancalari, E. Caffeine: Some of the Evidence behind Its Use and Abuse in the Preterm Infant. Neonatology 2022, 119, 428–432. [Google Scholar] [CrossRef] [PubMed]
- Wintermark, P.; Mohammad, K.; Bonifacio, S.L.; Newborn Brain Society Guidelines and Publications Committee. Proposing a care practice bundle for neonatal encephalopathy during therapeutic hypothermia. Semin. Fetal Neonatal. Med. 2021, 26, 101303. [Google Scholar] [CrossRef] [PubMed]
- Mike, J.K.; White, Y.; Ha, J.; Iranmahboub, A.; Hawkins, C.; Hutchings, R.S.; Vento, C.; Manzoor, H.; Wang, A.; Goudy, B.D.; et al. Perinatal Caffeine Administration Improves Outcomes in an Ovine Model of Neonatal Hypoxia-Ischemia. Stroke 2024, 55, 2705–2715. [Google Scholar] [CrossRef] [PubMed]
- Jiang, L.; Lee Him, R.; Sihota, D.; Muralidharan, O.; Dominguez, G.; Harrison, L.; Vaivada, T.; Bhutta, Z.A. Supportive Care for Common Conditions in Small Vulnerable Newborns and Term Infants: The Evidence. Neonatology 2025, 122, 129–151. [Google Scholar] [CrossRef] [PubMed]
- Roșca, I.; Constantin, A.T.; Popescu, D.E.; Jura, A.M.C.; Miu, A.; Turenschi, A. Are We Able to Prevent Neonatal Readmission? A Retrospective Analysis from a Pediatrics Department in Ploiești, Romania. Medicina 2024, 60, 705. [Google Scholar] [CrossRef] [PubMed]
Table 1.
Baseline characteristics in neonates who did and did not receive aminophylline.
| Variable | Neonates Who Received Aminophylline (n = 196) | Neonates Who Did Not Receive Aminophylline (n = 1478) | p-Value |
|---|---|---|---|
| Hospital: | 0.32 | ||
| Tosamaganga | 98 (12.6) | 679 (87.4) | |
| Wolisso | 98 (10.9) | 799 (89.1) | |
| Source of admission: a | <0.0001 | ||
| Homebirth | 20 (7.4) | 252 (92.6) | |
| Inborn | 141 (11.3) | 1102 (88.7) | |
| Outborn | 33 (21.4) | 121 (78.6) | |
| Preeclampsia/eclampsia: | <0.0001 | ||
| Yes | 9 (29.0) | 22 (71.0) | |
| No | 131 (10.1) | 1169 (89.9) | |
| Not reported | 56 (16.3) | 287 (83.7) | |
| Primiparous: | 0.49 | ||
| Yes | 47 (10.3) | 410 (89.7) | |
| No | 88 (11.9) | 651 (88.1) | |
| Not reported | 61 (12.8) | 417 (7.2) | |
| Prolonged rupture of membranes: | 0.63 | ||
| Yes | 32 (13.1) | 213 (86.9) | |
| No | 151 (11.3) | 1182 (88.7) | |
| Not reported | 13 (13.5) | 83 (86.5) | |
| Amniotic fluid: | 0.002 | ||
| Clear | 133 (11.8) | 991 (88.2) | |
| Meconium-stained | 20 (6.9) | 270 (93.1) | |
| Not reported | 43 (16.5) | 217 (83.5) | |
| Mode of delivery: b | <0.0001 | ||
| Assisted breech | 12 (33.3) | 24 (66.7) | |
| Cesarean section | 48 (9.0) | 487 (91.0) | |
| Vaginal delivery | 131 (12.9) | 882 (87.1) | |
| Vacuum | 1 (1.7) | 59 (98.3) | |
| Single/multiple births: | <0.0001 | ||
| Single births | 134 (9.4) | 1284 (90.6) | |
| Multiple births | 52 (31.5) | 113 (68.5) | |
| Not reported | 10 (11.0) | 81 (89.0) | |
| Delayed cord clamping: | 0.09 | ||
| Yes | 41 (9.2) | 406 (90.8) | |
| No | 54 (11.4) | 419 (88.6) | |
| Not reported | 101 (13.4) | 653 (86.6) | |
| Sex: | 0.28 | ||
| Females | 88 (12.8) | 600 (87.2) | |
| Males | 108 (11.0) | 878 (89.0) | |
| Gestational age: | <0.0001 | ||
| <28 weeks | 15 (93.7) | 1 (6.3) | |
| 28–32 weeks | 30 (75.0) | 10 (25.0) | |
| 32–34 weeks | 50 (43.9) | 64 (56.1) | |
| 35–36 weeks | 44 (20.5) | 171 (79.5) | |
| 37–42 weeks | 35 (3.2) | 1048 (96.8) | |
| >42 weeks | 0 (0.0) | 35 (100.0) | |
| Not reported | 22 (12.9) | 149 (87.1) | |
| Birth weight classification: c | <0.0001 | ||
| Extremely low birth weight (<1000 g) | 17 (89.5) | 2 (10.5) | |
| Very low birth weight (1000–1499 g) | 60 (64.5) | 33 (35.5) | |
| Low birth weight (1500–2499 g) | 94 (21.3) | 347 (78.7) | |
| Normal birth weight (≥2500 g) | 24 (2.2) | 1081 (97.8) | |
| Apgar score at 5 min: | <0.0001 | ||
| <7 | 56 (19.2) | 236 (80.8) | |
| ≥7 | 95 (9.0) | 955 (91.0) | |
| Not reported | 45 (13.6) | 287 (86.4) | |
| Temperature, °C c | 35.0 (34.2–35.8) | 36.0 (35.2–36.7) | <0.0001 |
| Transcutaneous oxygen saturation, % d | 94 (85–96) | 95 (91–97) | 0.005 |
| Respiratory support: c | <0.0001 | ||
| Continuous positive airway pressure | 92 (40.7) | 134 (52.3) | |
| Oxygen therapy | 63 (12.9) | 424 (87.1) | |
| No support | 40 (4.2) | 905 (95.8) |
Data were summarized as n (%) or median (IQR). The percentages are row percentages. Data were not available for a 5, b 30, c 16, and d 174 subjects.
Table 2.
Neonatal diagnoses in neonates who did and did not receive aminophylline.
| Diagnosis | Neonates Who Received Aminophylline (n = 196) | Neonates Who Did Not Receive Aminophylline (n = 1478) | p-Value |
|---|---|---|---|
| Pneumonia/sepsis/meconium aspiration syndrome: | 0.0001 | ||
| Yes | 47 (7.6) | 569 (92.4) | |
| No | 149 (14.1) | 909 (85.9) | |
| Congenital malformations: | 0.04 | ||
| Yes | 1 (2.0) | 50 (98.0) | |
| No | 195 (12.0) | 1428 (88.0) | |
| Respiratory distress syndrome: | <0.0001 | ||
| Yes | 67 (40.8) | 97 (59.1) | |
| No | 129 (8.5) | 1381 (91.5) | |
| Feeding problems: | 0.01 | ||
| Yes | 0 (0.0) | 40 (100.0) | |
| No | 196 (12.0) | 1438 (88.0) | |
| Hyperbilirubinemia: | <0.0001 | ||
| Yes | 13 (3.5) | 357 (96.5) | |
| No | 183 (14.0) | 1121 (86.0) | |
| Asphyxia: | 0.007 | ||
| Yes | 49 (16.4) | 249 (83.6) | |
| No | 147 (10.7) | 1229 (89.3) | |
| Prematurity: | <0.0001 | ||
| Yes | 146 (39.1) | 227 (60.9) | |
| No | 50 (3.8) | 1251 (96.2) | |
| Wet lung: | 0.19 | ||
| Yes | 11 (7.9) | 128 (92.1) | |
| No | 185 (12.0) | 1350 (88.0) |
Data were summarized as n (%) or median (IQR). The percentages are row percentages.
Table 3.
Discharge information of neonates who did and did not receive aminophylline.
| Discharge Information | Neonates Who Received Aminophylline (n = 196) | Neonates Who Did Not Receive Aminophylline (n = 1478) | p-Value |
|---|---|---|---|
| Hospital length of stay, days | 8 (3–19) | 5 (2–7) | <0.0001 |
| Max respiratory support during hospital stay: | <0.0001 | ||
| Continuous positive airway pressure | 108 (55.1) | 148 (10.0) | |
| Oxygen therapy | 38 (19.4) | 342 (23.2) | |
| No support | 39 (19.9) | 862 (58.3) | |
| Not reported | 11 (5.6) | 126 (8.5) | |
| Duration of the continuous positive airway pressure, days | 3 (2–5) | 2 (1–3) | <0.0001 |
| Intravenous line: | <0.0001 | ||
| Yes | 185 (94.4) | 873 (59.1) | |
| No | 5 (2.5) | 509 (34.4) | |
| Not reported | 6 (3.1) | 96 (6.5) | |
| Antibiotic therapy | 181 (92.3) | 790 (53.5) | <0.0001 |
| Kangaroo mother care a | 79 (41.8) | 123 (8.6) | <0.0001 |
| Feeding method: | <0.0001 | ||
| Maternal milk | 132 (67.3) | 1220 (82.5) | |
| Mixed | 27 (13.8) | 156 (10.5) | |
| Formula | 6 (3.1) | 51 (3.5) | |
| Not reported | 31 (15.8) | 51 (3.5) | |
| Discharge status: b | <0.0001 | ||
| Alive | 116 (59.2) | 1364 (93.0) | |
| Deceased | 69 (35.2) | 55 (3.7) | |
| Transferred | 11 (5.6) | 48 (3.3) |
Data were summarized as n (%) or median (IQR). The percentages are column percentages. Data were not available in a 48 and b 11 subjects.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
MDPI and ACS Style
Borellini, M.; Cavallin, F.; Mfaume, N.; Giday, E.H.; Endrias, T.; Tolera, J.; Belardi, P.; Manenti, F.; Putoto, G.; Pisani, L.; et al. Methylxanthine Treatment in Neonates Admitted to the Special Care Unit: An Observational Study in Low-Resource Settings. Children 2026, 13, 54. https://doi.org/10.3390/children13010054
AMA Style
Borellini M, Cavallin F, Mfaume N, Giday EH, Endrias T, Tolera J, Belardi P, Manenti F, Putoto G, Pisani L, et al. Methylxanthine Treatment in Neonates Admitted to the Special Care Unit: An Observational Study in Low-Resource Settings. Children. 2026; 13(1):54. https://doi.org/10.3390/children13010054
Chicago/Turabian StyleBorellini, Martina, Francesco Cavallin, Nasri Mfaume, Eleni Hagos Giday, Tarikua Endrias, Jiksa Tolera, Paolo Belardi, Fabio Manenti, Giovanni Putoto, Luigi Pisani, and et al. 2026. "Methylxanthine Treatment in Neonates Admitted to the Special Care Unit: An Observational Study in Low-Resource Settings" Children 13, no. 1: 54. https://doi.org/10.3390/children13010054
APA StyleBorellini, M., Cavallin, F., Mfaume, N., Giday, E. H., Endrias, T., Tolera, J., Belardi, P., Manenti, F., Putoto, G., Pisani, L., & Trevisanuto, D. (2026). Methylxanthine Treatment in Neonates Admitted to the Special Care Unit: An Observational Study in Low-Resource Settings. Children, 13(1), 54. https://doi.org/10.3390/children13010054
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
